Clinical Trials Browser

Phase 3 × Unknown × masitinib × Clear all

NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Phase 3 Unknown

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic